Immunicum
Gothenburg
About Immunicum
Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $54.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2018)
- Ticker: sto:IMMU
- Website: immunicum.se
- Phone: (463)141-5052
Industries & Categories
Biotechnology, Clinical Trials, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immunicum-2212968 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.